High-Dose Aspirin Is Required to Influence Plasma Fibrin Network Structure in Patients With Type 1 Diabetes
| Autor: | Ulf Adamson, Aleksandra Antovic, Sara Tehrani, Gun Jörneskog, Fariborz Mobarrez, Per-Eric Lins, Håkan Wallén, Koteiba Mageed |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Male
Cardiovascular and Metabolic Risk medicine.medical_specialty Endocrinology Diabetes and Metabolism Network structure Gastroenterology Drug Administration Schedule Fibrin law.invention Randomized controlled trial law Diabetes mellitus Internal medicine Internal Medicine medicine Humans In patient Chromatography High Pressure Liquid Original Research Glycemic Glycated Hemoglobin Advanced and Specialized Nursing Type 1 diabetes Aspirin biology business.industry medicine.disease Diabetes Mellitus Type 1 Endocrinology biology.protein Female business medicine.drug |
| Zdroj: | Diabetes Care |
| ISSN: | 1935-5548 0149-5992 |
| Popis: | OBJECTIVE Patients with type 1 diabetes form a less permeable fibrin network, which could contribute to their increased risk of cardiovascular disease (CVD). Low-dose aspirin treatment is the standard in the management of CVD; however, the effect seems reduced in patients with diabetes. We investigated the effects of low- and high-dose aspirin treatment on fibrin network formation in patients with type 1 diabetes (primary aim) and the possible interaction between the treatment effects of aspirin on fibrin network permeability and glycemic control in these patients (secondary aim). RESEARCH DESIGN AND METHODS Forty-eight patients (24 subjects with good [HbA1c 8.4%] glycemic control) were randomly assigned to treatment with 75 or 320 mg/day aspirin during 4 weeks in a crossover fashion. A 4-week washout period separated the treatment periods. The plasma fibrin network was assessed by determination of the permeability coefficient (Ks). RESULTS Treatment with 75 mg aspirin did not influence fibrin network permeability (Ks). However, Ks increased significantly during treatment with 320 mg aspirin (P = 0.004), and a significant treatment effect was seen compared with treatment with 75 mg aspirin (P = 0.009). The increase in Ks during high-dose aspirin treatment was significant in patients with poor glycemic control (P = 0.02), whereas Ks only tended to increase in patients with good glycemic control (P = 0.06). CONCLUSIONS A high dose of aspirin is required to influence fibrin network permeability in patients with type 1 diabetes. The observed lack of effect with low-dose aspirin may contribute to aspirin treatment failure in diabetes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|